Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1/2 1

Status

Active not recruiting 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Wilms Tumor 5Rhabdoid Tumor 5Neuroectodermal Tumors, Primitive, Peripheral 5Neuroblastoma 5Medulloblastoma 5Lymphoma, Non-Hodgkin 5Histiocytosis, Langerhans-Cell 5Hepatoblastoma 5Glioma 5Ependymoma 5Sarcoma 4Rhabdomyosarcoma 4Osteosarcoma 4Central Nervous System Neoplasms 4Sarcoma, Ewing 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neuroendocrine Tumors 2Lung Neoplasms 2Burkitt Lymphoma 2Xanthogranuloma, Juvenile 1Pancreatic Neoplasms 1Pancreatic Intraductal Neoplasms 1Non functioning pancreatic endocrine tumor 1Neoplasm Metastasis 1Lymphoma, B-Cell 1Lymphoma 1Histiocytic Sarcoma 1Familial ependymoma 1Carcinoma, Non-Small-Cell Lung 1Adenoma, Islet Cell 1

Interventions

Carboplatin 106Pemetrexed 74Paclitaxel 58Cisplatin 52Erlotinib Hydrochloride 51Radiotherapy 49Docetaxel 43Gemcitabine 41Bevacizumab 41pembrolizumab 30Nivolumab 25Radiosurgery 21Etoposide 20durvalumab 13Cetuximab 13Specimen Handling 12Ipilimumab 12Magnetic Resonance Spectroscopy 11Gefitinib 11Vinorelbine 10Taxes 10Radiation 10Albumin-Bound Paclitaxel 10osimertinib 9Biopsy 9vandetanib 8Topotecan 7Platinum 7Irinotecan 7Drug Therapy 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Lung Neoplasms × Phantoms, Imaging × Clear all
NCT03831932 2026-05-28

Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
22 enrolled 12 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01696968 2026-04-30

Screening for Lung Cancer in Older Patients (PLCO Screening Trial)

National Cancer Institute (NCI)

Phase NA Active not recruiting
154,901 enrolled 17 charts
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡